Company Spotlight: Pathwai EchoNext - Finding Structural Heart Disease on a Routine ECG

This episode examines the FDA 510(k) clearance summary for Pathwai's EchoNext, a software tool that analyzes standard 12-lead ECGs to flag suspected structural heart disease. We unpack the performance metrics from a 102,219-patient validation dataset, detailing its sensitivity, specificity, and six clinical sub-labels. Listeners will learn how this notification software functions, its limitations, and what it means for clinical workflows.

Key points

• EchoNext uses a deep neural network to analyze 12-lead ECG waveforms and basic demographics to flag suspicion of structural heart disease.
• The software provides a primary structural heart disease notification and up to six sub-labels, including left ventricular systolic dysfunction and aortic stenosis.
• Validation was performed on a dataset of 102,219 unique patients across four health systems, comparing ECG analysis against a ground truth of transthoracic echocardiograms.
• For the primary structural heart disease output, EchoNext achieved a sensitivity of 73.7% and a specificity of 75.2%.
• EchoNext is cleared as a notification tool parallel to standard of care; it cannot be used to rule out disease or on patients with implanted pacemakers.

Source: FDA 510(k) summary K260332: EchoNext (Pathwai) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Pathwai · Product: EchoNext · FDA 510(k) K260332

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-pathwai-echonext-finding-structural-heart-disease-on-f903d6